A Randomized Multicenter Trial Comparing and Efficacy of Simvastatin and Fluvastatin

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Lipid Metabolism

Background:

• Hydroxymethylglutaryl co-enzyme A reductase inhibitors are standard treatments for hypercholesterolemia.
• Accurate comparisons of drug potency and efficacy are crucial for clinical decision-making and payer assessments.
• Simvastatin and fluvastatin represent key agents within this therapeutic class.

Purpose of the Study:

• To compare the relative potency and hypolipidemic efficacy of simvastatin and fluvastatin.
• To evaluate dose-response relationships for both simvastatin and fluvastatin in hypercholesterolemic patients.

Main Methods:

• A balanced, double-blind, incomplete block study design involving 158 hypercholesterolemic patients across seven lipid clinics.
• Randomized assignment to three of five treatment arms: simvastatin (5, 10, 20 mg) or fluvastatin (20, 40 mg) for three 5-week periods.
• Lipid levels measured by a standardized central laboratory at the end of each treatment period.

Main Results:

• Simvastatin demonstrated greater reductions in low-density lipoprotein cholesterol (LDL-C) compared to fluvastatin at equivalent doses.
• The simvastatin/fluvastatin milligram potency ratio for LDL-C reduction was 6.8.
• At 20 mg, simvastatin doubled the LDL-C lowering effect of fluvastatin, with 46% of patients reaching NCEP LDL-C targets versus 12% for fluvastatin.

Conclusions:

• Fluvastatin 40 mg daily is comparable in efficacy to simvastatin 5 mg daily.
• Higher doses of simvastatin offer significantly greater efficacy in managing primary hypercholesterolemia.
• Simvastatin exhibits superior potency and effectiveness in lowering LDL-C compared to fluvastatin.